RELATED STUDY
A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019
Key Findings: Cannabis-based medicine likely has a favorable risk-benefit ratio in epilepsy and chronic noncancer pain, but for most other conditions the evidence is weak or inconclusive.
Type of Study: Meta-analysis
Study Sample Size: 198
Study Result: Inconclusive
Research Location(s): United States
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinoid (unspecified), Pharma THC, Pharma CBD
Phytocannabinoid Source: Not Applicable
Citation: Jugl S, et al. A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019. Med Cannabis Cannabinoids. 2021; 4:21-42. doi: 10.1159/000515069
Authors: Jugl S, Okpeku A, Costales B, Morris EJ, Alipour-Haris G, Hincapie-Castillo JM, Stetten NE, Sajdeya R, Keshwani S, Joseph V, Zhang Y, Shen Y, Adkins L, Winterstein AG, Goodin A
